Last reviewed · How we verify

F-18 FPCIT

Asan Medical Center · Phase 3 active Small molecule

F-18 FPCIT is a fluorine-18 labeled dopamine transporter (DAT) imaging agent that binds to dopamine transporters in the striatum to visualize dopaminergic neuronal integrity via PET imaging.

F-18 FPCIT is a fluorine-18 labeled dopamine transporter (DAT) imaging agent that binds to dopamine transporters in the striatum to visualize dopaminergic neuronal integrity via PET imaging. Used for Imaging of dopamine transporters in the striatum to aid in the diagnosis of Parkinson's disease and differentiation from essential tremor and other parkinsonian syndromes.

At a glance

Generic nameF-18 FPCIT
SponsorAsan Medical Center
Drug classPET imaging agent / Radiopharmaceutical
TargetDopamine transporter (DAT)
ModalitySmall molecule
Therapeutic areaNeurology / Diagnostic Imaging
PhasePhase 3

Mechanism of action

F-18 FPCIT is a positron emission tomography (PET) radiopharmaceutical that selectively binds to dopamine transporters located on presynaptic dopaminergic neurons. By measuring the uptake and distribution of this tracer in the striatum, clinicians can assess the density and function of dopaminergic neurons, enabling differentiation of neurodegenerative parkinsonian syndromes and detection of dopaminergic dysfunction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: